Clinical Trial Update: Effect of Sodium Glucose co Transporter 2 Inhibitor ( SGLT2) on Proteinuria in Diabetic Patients [Phase 4]

View source ↗

Summary

Phase 4 trial assessing the effect of an SGLT2 inhibitor on proteinuria in patients with diabetic nephropathies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy

Snippet

Sponsor: Nahla H Tohami | Conditions: Diabetic Nephropathies | Phase 4 | Status: UNKNOWN